Earnings summaries and quarterly performance for CLSD.
Executive leadership at CLSD.
Board of directors at CLSD.
Research analysts who have asked questions during CLSD earnings calls.
Andreas Argyrides
Oppenheimer & Co. Inc.
2 questions for CLSD
Also covers: AQST, ARSP, GOSS +7 more
DC
Debanjana Chatterjee
JonesTrading Institutional Services
2 questions for CLSD
Also covers: ABSI, EYPT, KALV +2 more
JW
Jonathan Wolleben
JMP Securities, a Citizens Company
2 questions for CLSD
Also covers: ALT, BCRX, DBVT +5 more
SB
Serge Belanger
Needham & Company
2 questions for CLSD
Also covers: AMPH, ARQT, BCRX +12 more
Annabel Samimy
Stifel Financial Corp.
1 question for CLSD
Also covers: ALT, APLS, CARA +14 more
AA
Antonio Arce
H.C. Wainwright & Co.
1 question for CLSD
Also covers: AKBA, CODX, ENTA
DG
Daniil Gataulin
Chardan
1 question for CLSD
Also covers: CGTX, EYPT, KOD +3 more
JM
Jae Mom
Stifel
1 question for CLSD
JW
Jon Wolleben
Citizen JMP
1 question for CLSD
Also covers: BCRX, MDGL, MIRM +3 more
YC
Yi Chen
H.C. Wainwright & Co.
1 question for CLSD
Also covers: ANGO, APDN, BLFS +22 more
Recent press releases and 8-K filings for CLSD.
Clearside Biomedical Files for Chapter 11 and Faces Nasdaq Delisting
CLSD
Legal Proceedings
Delisting/Listing Issues
M&A
- Clearside Biomedical, Inc. filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code on November 23, 2025, in the U.S. Bankruptcy Court for the District of Delaware.
- The company intends to pursue a strategic sale of its business through an auction and sale process under Section 363 of the U.S. Bankruptcy Code, with the objective to maximize stakeholder value and sell substantially all of its assets.
- On November 24, 2025, Nasdaq notified the company that its common stock will be delisted from Nasdaq, with trading to be suspended at the opening of business on December 1, 2025.
- The company does not intend to appeal the delisting, and its common stock is expected to begin trading exclusively on the over-the-counter (OTC) market on December 1, 2025, under the symbol CLSDQ.
Nov 25, 2025, 9:06 PM
Clearside Biomedical Implements Reverse Stock Split
CLSD
Delisting/Listing Issues
Proxy Vote Outcomes
- Clearside Biomedical, Inc. filed an amendment to its Certificate of Incorporation to effect a one-for-fifteen (1-for-15) reverse stock split of its common stock.
- The reverse stock split and a reduction in authorized shares will become effective at 5:00 p.m. Eastern Time on September 12, 2025.
- As a result, the total number of authorized common shares will be reduced from 400,000,000 to 26,666,666.
- The company's common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market on September 15, 2025.
- No fractional shares will be issued; stockholders will receive a cash payment in lieu thereof.
Sep 11, 2025, 11:24 AM
Clearside Biomedical, Inc. to Implement Reverse Stock Split
CLSD
Proxy Vote Outcomes
Delisting/Listing Issues
- Clearside Biomedical, Inc. filed a Certificate of Amendment to implement a one-for-fifteen (1-for-15) reverse stock split of its common stock.
- The reverse stock split will be effective at 5:00 p.m. Eastern Time on September 12, 2025.
- Concurrently, the total number of authorized common shares will be reduced from 400,000,000 to 26,666,666.
- The company's common stock is expected to begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on September 15, 2025.
- Stockholders who would otherwise receive fractional shares will instead receive a cash payment.
Sep 11, 2025, 11:20 AM
Quarterly earnings call transcripts for CLSD.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more